海捷投资控股合伙人 海捷投资首席运营官 海捷医疗董事长 长江商学院EMBA 湖南大学管理学博士 关注健康医疗类、文化体育类成长期项目的投资。
项目需求点击详情
海捷投资控股合伙人 海捷医药产业基金CEO 海捷慕士基金CEO 武汉大学EMBA 关注天使投资、VC类投资、物联网项目的投资。
项目需求点击详情
海捷投资控股集团董事长，湖南省股权投资协会执行会长，中国医药创新促进会医药创新投资专业委员会副主委，湖南海归协会名誉会长，中欧国际工商学院EMBA，湖南大学管理学博士、研究员，悉尼大学访问学者，湖南大学金融与投资管理研究中心主任。 1997年，储慧斌先生加入湘财证券，历任投资银行总部副总经理、企业融资部总经理、股票承销部总经理，曾成功主持三一重工、电广传媒、隆平高科、湘酒鬼、大湖股份、金健米业等十多家企业的IPO或再融资，在投行领域拥有深厚资历和广泛人脉。2002年，储慧斌先生离开湘财证券自行创业，2003年即主持了当年中国资本市场最大私募融资项目—北方电力60亿元人民币融资。 储慧斌先生先后组建了海捷先进装备产业基金（国家创业引导基金）、海捷津杉创投基金、海捷医药产业基金、海捷慕士创投基金和海捷领投系列基金，凭借其丰富的投行与投资经验，在企业资源整合、业务发展、资本运作等方面为被投企业提供了独到价值。 储慧斌先生专注投行与投资20年，先后投资了70余家企业，其中A股上市9家，香港上市5家，新三板挂牌10家，创新层3家，IPO在会审核3家。 储慧斌先生曾连任第九、十届全国青联委员。
项目需求点击详情
Dr. Tony Tong is a Vice President of Decheng Capital and has been with the firm since May 2014. He has an interest in diverse sectors within the China healthcare industry. He currently serves on the boards of CardiMED and Insight Lifetech. Prior to joining Decheng Capital, Dr. Tong was a Vice President at Mingly China Growth Fund (MCGF), focusing on evaluating investment opportunities in the healthcare sector and serving on the boards of Yocaly (acquired by Lepu Medical), Family of Health (partially acquired by Sunshine Insurance), Sonicmed and Baifendian Technology. From 2009 to 2012, Dr. Tong was Senior Investment Associate at Yifang Ventures, a venture capital investment and asset management firm founded by Dr. Eric Xu, the Co-founder of Baidu.com. Dr. Tong received his PhD in Biochemistry and Molecular Biology from Institute of Biophysics of Chinese Academy of Science, a BS degree in Life Science from University of Science and Technology of China and the second BS degree in Economics from Peking University.
项目需求点击详情
Dr. Nick Pliam is a Principal at Decheng Capital. He has been with the firm since its inception and Bay City Capital since 2005. Dr. Pliam is trained as a cell biologist and orthopedic surgeon, and has worked within, and as an advisor to, biopharmaceutical and medical technology companies. He is a founder of Guided Delivery Systems, a medical device company developing a minimally invasive technology for treatment of mitral valve regurgitation, and a founder of Pharmagenesis, a natural products pharmaceutical company. As an independent consultant and as managing director of a boutique investment banking firm, he has advised life science companies and investors (including Biomet, Devax, Hanwha Pharmaceutical, Marubeni Group, Micrus Endovascular, and Triage Medical) on financing transactions and strategy. He is an inventor with patents in medical devices and biopharmaceuticals. Dr. Pliam serves on the boards of directors of Nevro Corporation (NYSE: NVRO) and a former member of the board of IDev Technologies (acquired by Abbott Laboratories). He holds an MD from Dartmouth Medical School and a PhD in Endocrine Physiology from the University of California, San Francisco. Dr. Pliam completed his surgical training at UCSF and Stanford University. He completed his undergraduate degree in German literature from the University of California, Berkeley, and studied at Georg August Universitaet in Goettingen.
项目需求点击详情
Dr. Qiang Xu is a Principal at Decheng Capital and has been with the firm since its inception. He is currently serving on the boards of BCFoods and GYT HealthCare Services. He has over 14 years of experience from biotechnology start-ups to pharmaceutical companies and also has extensive experience in agricultural biotechnology. He was most recently Vice President of Research at Osel and the principal investigator for multiple grants funded by the NIH and other foundations. Dr. Xu started his biotechnology career at Bayer, worked at Pan Pacific Pharmaceuticals as a director, and Scios as a member of the Alzheimers Disease Discovery Program. He has published over 30 peer reviewed papers, and 50 conference presentations, and is the co-inventor of 10 patents or applications. Dr. Xu received his BS in agronomy and MS in Crop Sciences (with Professor Yu Songlie, an academician of the Chinese Academy of Engineering) and PhD in plant physiology from Kansas State University. He completed his postdoctoral training at the University of California, Berkeley.
项目需求点击详情
Mr. Victor E. Tong, Jr. is a Partner at Decheng Capital and has been with the firm since its inception. At Decheng, Mr. Tong focuses on investments in biotechnology and medical technology companies in China and US. Mr. Tong currently serves on the boards of AccuraGen, EpimAb Biotherapeutics, GenapSys, GeneMDx, Levitas, ReadCoor and SentreHeart. He previously served on the boards of past Decheng companies Cirina (acquired by GRAIL) and GeneWEAVE Biosciences (acquired by Roche). Mr. Tong’s investment portfolio also includes 3SBio (1530.HK), Apexigen, ARMO Biosciences, Cellular Research (acquired by Becton Dickinson), China Biologic Products (NASDAQ: CBPO), Hummingbird Bioscience, Invitae (NASDAQ: NVTA) and SINOMED. Prior to joining Decheng, Mr. Tong was a Principal at Bay City Capital and was a member of the founding team of Nevro (NYSE: NVRO), a Bay City Capital-originated medical device company. He also played a key role in the firm’s investments in Cadence Pharmaceuticals (acquired by Mallinckrodt), GenturaDx (acquired by Luminex), Ion Torrent Systems (acquired by Life Technologies) and NextWave Pharmaceuticals (acquired by Pfizer). Prior to joining Bay City, Mr. Tong was an investment banker with Morgan Stanley, where he advised healthcare companies on initial public offerings and specialized in strategic advisory work. Prior to Morgan Stanley, Mr. Tong was an entrepreneur at Hana Biosciences (acquired by Spectrum Pharmaceuticals), where he was responsible for pipeline development, licensing and product launch for cancer products. Mr. Tong began his career participating in The Human Genome Project and its race to sequence the human genome as a research assistant at Incyte in 1999. Mr. Tong is a graduate of the University of California, Berkeley, where he earned a BA degree in Molecular and Cell Biology and a BS degree in Business Administration from the Haas School of Business.
项目需求点击详情
Dr. Min Cui is the Founder and Managing Director of Decheng Capital. At Decheng Capital, Dr. Cui has been focusing on partnerships with entrepreneurs and building biotechnology and medical technology companies in China and US. He is currently a board member of AccuraGen, Ariagen, ARMO BioSciences, CardioMed, EpimAb Biotherapeutics, GenapSys, GeneMDx, GRAIL (observer), Hummingbird Bioscience, Ketai Medical, Levitas, and SINOMED. His investment portfolio also includes 3SBio (HK Stock Exchange: 1530), China Biologic Products (NASDAQ: CBPO), Cirina (acquired by GRAIL), Epizyme (NASDAQ: EPZM), GeneWEAVE Biosciences (acquired by Roche), GenturaDx (acquired by Luminex), and Ion Torrent Systems (acquired by Life Technologies). Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm in San Francisco. At Bay City, he led investment opportunities in US as well as all its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui received his PhD in Cancer Biology from Stanford University and his BS and MS in Molecular Biology from Peking University. Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America.
项目需求点击详情
姜涛女士是朗然资本的创始合伙人。她在医疗领域不同业态工作近二十年，对中国医疗健康行业状态及发展有深刻的认知与见地。她曾在知名三甲医院承担科室管理工作，对医院运营及民众医疗需求了解非常深入。她曾在飞利浦家庭医疗保健部担任销售及市场总监，对医药销售管理、渠道建立及市场营销均有丰富的实际经验。她曾在医疗创投企业担任CEO和董事，熟悉科技企业从初建到运作的实践过程。她曾担任多家风投机构医疗行业高级咨询顾问，对业内资本运作方式及投资方向有清晰的观点与认识。 姜涛女士拥有中国医科大学临床医学专业学士学位，取得中科院心理所人力资源管理硕士学历，具有主治医师资质。
项目需求点击详情
潘育新先生是朗然资本的创始合伙人。他熟悉大型综合超市、超级市场、便利店、药妆店等各业态的投资、发展、采购、运营、财务等多方面业务，并拥有超过十五年的股权与创业投资管理经历，在企业并购重组和公司全面运营管理方面有着丰富的经验。他曾在联华超市股份有限公司担任高管职位，分管投资工作，主导和参与近20项并购重组项目，并领导快客便利和联华复星药业取得了富有成效的业绩。此外，潘育新先生还是德式Board Game行业的权威人士，创立和投资了两家企业。 潘育新先生拥有哈尔滨工业大学管理学硕士学位，并在2013年获得美国亚利桑那州立大学工商管理硕士学位和上海国家会计学院财务总监资格培训证书。
项目需求点击详情
李笙凯 可可资本合伙人 李笙凯先生曾在正略钧策和Hay Group从事高端咨询服务，后来加入清华科技园，参与创立InnoSpace，从事创业孵化工作多年，孵化的企业有国神光电、十年后、游友移动等。 加入可可资本（数元创投）后，李先生充分发挥在清华大学机械工程系和工业工程系的多年历练，在机器人和人工智能领域精耕细作，成为该领域的顶级投资专家，投资项目有昂华自动化（300009-上海科技创新板）、码隆科技、思岚科技、翼菲自动化、玻森数据、无距科技、未来机器人、优爱宝（836953-新三板）、恒正精机等；在TMT领域，投资了钛马车联网、易所试（430309-新三板）等项目。 李笙凯先生是马来西亚华裔，毕业于清华大学，拥有清华大学工学学士和工学硕士学位。现为中国机械工程学会机器人分会委员，清华大学全球产业4.5研究院产业菁英项目导师。
项目需求点击详情
李俊兵 可可资本合伙人 李俊兵先生曾先后任职张江高新技术创业服务中心投资经理、浦东生物投资基金高级投资经理、上海汉世纪投资管理公司副总裁，服务于多家知名投资机构，有15年的VC和PE的股权投资从业经验。 李先生主导或参与的投资项目有凯赛生物、复旦张江（01349）、易所试（430309）、安硕信息（ 300380.SZ ）、百林通讯（430329）、非码网络、杠点信息、闪雷信息，以及优爱宝机器人和华亚微电子等。在汽车电子、电力电子以及汽车后服务市场等领域众多的投资经验和丰富的增值服务资源。 李先生有积极主动的增值服务意识，把投资人参与企业的价值创造认为是资本增值的不二法门，在创业辅导和产业资源对接方面得到了创业者们的广泛认可。 李俊兵先生毕业于东华大学，拥有东华大学管理学硕士学位。
项目需求点击详情
微信公众号
